JUPITER, Fla., April 15, 2013 /PRNewswire/ -- BioRestorative Therapies, Inc. ("BRT" or the "Company") (OTCBB: BRTX), a life sciences company focused on adult stem cell based cellular therapies for various personal medical applications, announced today that it has been invited to present at the 5th International Congress on Prediabetes and the Metabolic Syndrome in Vienna, Austria. The conference will take place April 18th-20th, 2013 at the Austria Center Vienna and will highlight early interventions for diabetes, dysglycemia, and surgery in the treatment of obesity and diabetes, where world leaders and specialists will discuss pioneering research in these areas.
BRT Chief Scientist and Vice President of Research and Development, Francisco Silva, will be presenting the Company's research on Human Metabolically Active Brown Adipose Tissue Derived Stem Cells on April 19, 2013 from 2:00-3:30 local time. This research is a result of the scientific work BRT has been performing pursuant to its ThermoStem™ Program, which focuses on treatments using brown fat stem cells for metabolic disorders and obesity, primarily focusing on potentially preventing the onset of Type 2 Diabetes.
The principal sponsor of the conference is Novo Nordisk, with additional sponsorship from Bayer and Sanofi Aventis. Conference attendees are expected to be primarily clinical practitioners and researchers, but with corporate professionals and health administrators in attendance as well. Professionals with expertise in the field of endocrinology are expected to make up the majority of conference attendance with diabetes being the largest field of interest.
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc. ("BRT") develops medical procedures using cell and tissue protocols, primarily involving adult stem cells, and allowing patients to undergo minimally invasive cellular-based treatments. BRT is developing the following scientific initiatives: Our brtxDISC™ Program (Disc Implanted Stem Cells) offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures. Our ThermoStem™ Program focuses on treatments, using brown fat stem cells, for metabolic disorders (diabetes, heart disease, etc.) and obesity primarily focusing on potentially preventing the onset of Type 2 Diabetes. Initial research indicates that increased amounts of brown fat in the body may be responsible for additional caloric burning as well as reduced glucose and lipid levels in the body. The Company also offers plant stem cell-based facial creams and products under the Stem Pearls® brand at www.stempearls.com.
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including those set forth in the Company's Form 10-K filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
SOURCE BioRestorative Therapies, Inc.